Vontobel Holding Ltd. Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Vontobel Holding Ltd. reduced its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 60.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,984 shares of the company’s stock after selling 4,535 shares during the quarter. Vontobel Holding Ltd.’s holdings in Krystal Biotech were worth $467,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Segall Bryant & Hamill LLC raised its holdings in Krystal Biotech by 352.4% during the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after purchasing an additional 122,407 shares during the last quarter. State Street Corp grew its position in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after acquiring an additional 119,936 shares during the period. Franklin Resources Inc. grew its position in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after acquiring an additional 62,178 shares during the period. Braidwell LP lifted its stake in shares of Krystal Biotech by 57.4% during the third quarter. Braidwell LP now owns 168,691 shares of the company’s stock worth $30,707,000 after purchasing an additional 61,512 shares in the last quarter. Finally, Edgestream Partners L.P. acquired a new position in shares of Krystal Biotech during the third quarter worth about $5,872,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $182.62 on Friday. The stock’s fifty day moving average price is $157.18 and its two-hundred day moving average price is $175.18. The company has a market cap of $5.25 billion, a price-to-earnings ratio of 103.18 and a beta of 0.84. Krystal Biotech, Inc. has a 52-week low of $107.50 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company’s revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.30 EPS. On average, equities analysts predict that Krystal Biotech, Inc. will post 3.22 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 14.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday. Citigroup raised their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday. HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $210.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).